PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8871604-6	1996	Phorbol 12-myristate 13-acetate (PMA), an activator of PKC, resembled IL4 in decreasing the expression of CD38, and either staurosporine or H7 abolished this effect.	Tetradecanoylphorbol Acetate	0-31	CD38 molecule	Homo sapiens	106-110	
16111532-4	2005	TPA induced the following antigens in decreasing order of the change: CD11c, CD9, CD11b, CD54, CD38, CD45RO and CD66c, with repression of CD4, CD117, CD95, CD71 and CD64.	Tetradecanoylphorbol Acetate	0-3	CD38 molecule	Homo sapiens	95-99	
8871604-6	1996	Phorbol 12-myristate 13-acetate (PMA), an activator of PKC, resembled IL4 in decreasing the expression of CD38, and either staurosporine or H7 abolished this effect.	Tetradecanoylphorbol Acetate	33-36	CD38 molecule	Homo sapiens	106-110	
26229980-3	2014	Previous studies, using phorbol-myristate-acetate (PMA) as a differentiating agent, have suggested that the CD34+/CD38+ TF-1 cell line may be used as one model to study the differentiation processes of HPCs.	Tetradecanoylphorbol Acetate	24-49	CD38 molecule	Homo sapiens	114-118	
8759717-3	1996	We show here that expression of CD38 is increased in the Jurkat T cell line after treatment with agents that augment intracellular cAMP, with the permeant cAMP analogue dibutyryl-cAMP (db-cAMP), and also with PMA, which activates protein kinase C. Treatment of human PBL T cells with db-cAMP or submitogenic doses of PMA also increased CD38 expression.	Tetradecanoylphorbol Acetate	209-212	CD38 molecule	Homo sapiens	32-36	
31649684-7	2019	Ex vivo examination of CD38+HLA-DR+CD8+ T cells indicated that this subset of cells displayed stronger secretion of IFN-gamma and IL-2 before and after a 6-h stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin (ION) relative to healthy CD38+HLA-DR+CD8+ T cells, indicating the functional feasibility of CD38+HLA-DR+CD8+ T cells.	Tetradecanoylphorbol Acetate	175-206	CD38 molecule	Homo sapiens	23-27	
31649684-7	2019	Ex vivo examination of CD38+HLA-DR+CD8+ T cells indicated that this subset of cells displayed stronger secretion of IFN-gamma and IL-2 before and after a 6-h stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin (ION) relative to healthy CD38+HLA-DR+CD8+ T cells, indicating the functional feasibility of CD38+HLA-DR+CD8+ T cells.	Tetradecanoylphorbol Acetate	175-206	CD38 molecule	Homo sapiens	253-257	
31649684-7	2019	Ex vivo examination of CD38+HLA-DR+CD8+ T cells indicated that this subset of cells displayed stronger secretion of IFN-gamma and IL-2 before and after a 6-h stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin (ION) relative to healthy CD38+HLA-DR+CD8+ T cells, indicating the functional feasibility of CD38+HLA-DR+CD8+ T cells.	Tetradecanoylphorbol Acetate	175-206	CD38 molecule	Homo sapiens	253-257	
31649684-7	2019	Ex vivo examination of CD38+HLA-DR+CD8+ T cells indicated that this subset of cells displayed stronger secretion of IFN-gamma and IL-2 before and after a 6-h stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin (ION) relative to healthy CD38+HLA-DR+CD8+ T cells, indicating the functional feasibility of CD38+HLA-DR+CD8+ T cells.	Tetradecanoylphorbol Acetate	208-211	CD38 molecule	Homo sapiens	23-27	
31649684-7	2019	Ex vivo examination of CD38+HLA-DR+CD8+ T cells indicated that this subset of cells displayed stronger secretion of IFN-gamma and IL-2 before and after a 6-h stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin (ION) relative to healthy CD38+HLA-DR+CD8+ T cells, indicating the functional feasibility of CD38+HLA-DR+CD8+ T cells.	Tetradecanoylphorbol Acetate	208-211	CD38 molecule	Homo sapiens	253-257	
31649684-7	2019	Ex vivo examination of CD38+HLA-DR+CD8+ T cells indicated that this subset of cells displayed stronger secretion of IFN-gamma and IL-2 before and after a 6-h stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin (ION) relative to healthy CD38+HLA-DR+CD8+ T cells, indicating the functional feasibility of CD38+HLA-DR+CD8+ T cells.	Tetradecanoylphorbol Acetate	208-211	CD38 molecule	Homo sapiens	253-257	
26229980-3	2014	Previous studies, using phorbol-myristate-acetate (PMA) as a differentiating agent, have suggested that the CD34+/CD38+ TF-1 cell line may be used as one model to study the differentiation processes of HPCs.	Tetradecanoylphorbol Acetate	51-54	CD38 molecule	Homo sapiens	114-118